BOSTON and LAUSANNE,
Switzerland, June 15, 2022 /PRNewswire/ -- SOPHiA GENETICS SA
(Nasdaq: SOPH) ("the Company"), is pleased to announce the
Annual General Meeting ("the Meeting") was held at the
Company's headquarters, rue du Centre 172, 1025 St-Sulpice, VD,
Switzerland, earlier today at
2:00 p.m. CET (8:00 a.m. EDT).
The Company's shareholders approved each agenda item presented
at the Meeting. The Meeting minutes and detailed voting results by
agenda item have been published on the Company's website in the
investor section. The detailed voting results will also be filed
with the U.S. Securities and Exchange Commission on a Report on
Form 6-K.
Additionally, the Company would like to welcome the newly
appointed director, Jean-Michel Cosséry to its Board of
Directors. Mr. Cosséry will be a strong addition to the Board of
Directors as he offers more than 25-years of industry experience.
The Company looks forward to Mr. Cosséry's future
contributions.
The Company would also like to thank all shareholders
represented or having voted by mail for their valued commitment and
support.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology
company dedicated to establishing the practice of data-driven
medicine as the standard of care and for life sciences research. It
is the creator of the SOPHiA DDM™ Platform, a cloud-native platform
capable of analyzing data and generating insights from complex
multimodal data sets and different diagnostic modalities. The
SOPHiA DDM™ Platform and related solutions, products and services
are currently used by over 790 hospital, laboratory, and biopharma
institutions globally. For more information, visit
SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn and Instagram.
Where others see data, we see answers.
SOPHiA GENETICS Forward-Looking
Statements
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this document speak
only as of the date of this press release. We expressly disclaim
any obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based unless required to
do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Logo-
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg